In the 71 patients with crizotinib-pretreated ALK+ NSCLC, median overall survival was 30.1 months (95% CI: 21.4–55.0), and 5-year overall survival probability was 35% (95% CI: 22–49). Here, ALK is linked to non-small cell lung carcinoma.